Organovo Holdings, Inc. (ONVO)
After hours:
| Previous close | 1.1500 |
| Open | 1.1500 |
| Bid | 0.9546 x 100 |
| Ask | 1.2800 x 100 |
| Day's range | 1.1000 - 1.1900 |
| 52-week range | 0.8900 - 2.0900 |
| Volume | |
| Avg. volume | 1,014,679 |
| Market cap | 11.085M |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1600 |
| Earnings date | 11 July 2024 - 15 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.55 |
GlobeNewswireOrganovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH). St
Insider MonkeyTop 15 3D Printing Companies in the US
In this article, we will take a look at the top 15 3D printing companies in the US. If you want to skip our detailed analysis, you can go directly to Top 5 3D Printing Companies in the US. Recent Trends in 3D Printing According to a report by Grand View Research, the global 3D […]
Simply Wall St.Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Organovo Holdings ( NASDAQ:ONVO ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.60m (loss widened by...
